CFO Mark Frost Buys $25,000 in Harvard Bioscience Stock Amidst Recent Insider Accumulation
HBIO sits 78% above its 52-week low of $2.813.
Summary
Harvard Bioscience's CFO, Mark Frost, purchased $25,000 worth of common stock, adding to a recent trend of insider buying following the company's debt refinancing and reverse stock split.
Key Events · Ownership and Investor Activity · HBIO
-
CFO Open Market Purchase
Mark T. Frost, Chief Financial Officer, purchased 5,000 shares of common stock for $25,000 at $5.00 per share on March 16, 2026.
-
Continued Insider Accumulation
This purchase adds to a pattern of insider buying, with three insiders accumulating over $177,000 in shares over the past 90 days.
-
Post-Reverse Stock Split Transaction
The transaction occurred shortly after the company's 10-for-1 reverse stock split on March 13, 2026.
Analysis · HBIO · Industrial Applications And Services
This open market purchase by CFO Mark Frost signals management confidence, especially coming after the company's significant net loss in FY2025 and a recent reverse stock split. The transaction contributes to a broader pattern of insider accumulation, with three insiders collectively buying over $177,000 in the last 90 days. This insider buying could be interpreted as a positive sign that management believes the company is undervalued, particularly after addressing going concern doubts through debt refinancing.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.6% of the 1725 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HBIO was trading at $5.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.4M. The 52-week trading range was $2.81 to $9.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.